US OptionsDetailed Quotes
FATE241018P5000
- 1.09
- 0.000.00%
15min DelayTrading Oct 18 16:00 ET
0.00High0.00Low
0.00Open1.09Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-23.54%PremiumOct 18, 2024Expiry Date1.84Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.90Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Fate Therapeutics Stock Discussion
Sign in to post a comment
$Metagenomi Technologies, LLC (MGX.US)$ $Lantronix (LTRX.US)$
$Fate Therapeutics (FATE.US)$
$Navitas Semiconductor (NVTS.US)$
Opened up some positions on these today.
Increased $Rivian Automotive (RIVN.US)$ , $X4 Pharmaceuticals (XFOR.US)$
Took profit on $FTC Solar (FTCI.US)$ , $GigaCloud Technology (GCT.US)$ and $Aurora Innovation (AUR.US)$
I'll be back in GCT and AUR for sure.
Still looking at $Spero Therapeutics (SPRO.US)$ and $Acacia Research (ACTG.US)$ too.
Exciting day for dips!
$Fate Therapeutics (FATE.US)$
$Navitas Semiconductor (NVTS.US)$
Opened up some positions on these today.
Increased $Rivian Automotive (RIVN.US)$ , $X4 Pharmaceuticals (XFOR.US)$
Took profit on $FTC Solar (FTCI.US)$ , $GigaCloud Technology (GCT.US)$ and $Aurora Innovation (AUR.US)$
I'll be back in GCT and AUR for sure.
Still looking at $Spero Therapeutics (SPRO.US)$ and $Acacia Research (ACTG.US)$ too.
Exciting day for dips!
1
1
$Fate Therapeutics (FATE.US)$
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...
$Fate Therapeutics (FATE.US)$ Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy
$Fate Therapeutics (FATE.US)$
NEWS
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
NEWS
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
1
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$Fate Therapeutics (FATE.US)$ Press Release: Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Dow Jones· 1 min ago
Dow Jones· 1 min ago
Analysts downgrade revenue estimates for next year and reduce loss estimates. The company's revenue is expected to decline by 92% annually by end of 2024, a shift from historical growth of 47% over the last five years. Fate Therapeutics is expected to lag the wider industry.
Fate Therapeutics' P/S ratio aligns with peers due to predicted revenue drop in following years. Given forecasted revenue slide and below par industry growth, future share price gains may be minimal. It's vital to consider the company's future prospects and not just its P/S ratio when deciding to sell stock.
$Abbott Laboratories (ABT.US)$ $American Public Education (APEI.US)$ $AstraZeneca (AZN.US)$ $Credit Suisse (CS.US)$ $Elevation Oncology (ELEV.US)$ $Esperion Therapeutics (ESPR.US)$ $Fate Therapeutics (FATE.US)$ $HUB Cyber Security (HUBC.US)$ $LivePerson (LPSN.US)$ $Movella Holdings (MVLA.US)$ $NextEra Energy (NEE.US)$ $UiPath (PATH.US)$ $ThermoGenesis (THMO.US)$ $PagerDuty (PD.US)$ $Science 37 (SNCE.US)$
4
No comment yet
Tonyco OP : Also, I took profit from: $SolarBank (SUUN.US)$, $AXT Inc (AXTI.US)$, $Polestar Automotive (PSNY.US)$ and $ACM Research (ACMR.US)$
Opened $SoFi Technologies (SOFI.US)$
SOFI is probably my least enthusiastic buy so far. It's super undervalued but faces immense short pressure.